Halozyme Therapeutics (HALO) Expected to Announce Quarterly Earnings on Thursday

Halozyme Therapeutics (NASDAQ:HALO) will likely be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $2.30 per share and revenue of $490.85 million for the quarter. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter last year, the company posted $1.54 EPS. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. On average, analysts expect Halozyme Therapeutics to post $8.31 EPS for the current fiscal year and $9.79 EPS for the next fiscal year.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $128.95 on Tuesday. Halozyme Therapeutics has a 52-week low of $61.22 and a 52-week high of $134.00. The company has a fifty day moving average of $114.12 and a 200-day moving average of $83.74. The company has a market capitalization of $14.64 billion, a P/E ratio of 26.38, a P/E/G ratio of 0.49 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. HC Wainwright increased their price objective on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Finally, Citizens Jmp increased their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.55.

Insider Transactions at Halozyme Therapeutics

In related news, Director Matthew L. Posard sold 18,996 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the sale, the director directly owned 58,839 shares in the company, valued at $6,339,313.86. This represents a 24.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 125,852 shares of company stock worth $13,538,046. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.